Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SyB C-1101 + Azacytidine in MDS
NCT02783547Phase 1Withdrawn
- Sponsor
- SymBio Pharmaceuticals
- Start
- Dec 2015
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of rigosertib in myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML), sponsored by SymBio Pharmaceuticals. Primary endpoint: Number of dose-limiting toxicity (DLT) up to 19 months. Planned start Dec 2015; status: withdrawn.
02
Drugs
rigosertib
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT02783547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02783547.